While I agree with what you're saying about NYAS in general, I believe there was another reason as well. While they were hoping to have the Journal by ASCO, the NYAS presentation gave them something to show in their booth at ASCO. They essentially let Dr. Ashkan do the video that duplicated what was presented at NYAS to show in their booth at ASCO.
Hopefully we'll get the Journal any day. Investors need to realize the Journal is in no way slowing the company's efforts at gaining regulatory approvals or approval of the FlaskWorks unit, but it's preventing them from discussing it because of the quiet period. I believe we'll all be happy once we know how close we really are to actual approvals or regulatory submissions.